Dr Reddy's Launches Generic Bridion Injection in US

Written By :  Parthika Patel
Published On 2026-08-04 14:34 GMT   |   Update On 2026-08-04 14:34 GMT
Advertisement

New Delhi: Dr Reddy's Laboratories on Tuesday said it has launched the generic version of Sugammadex injection indicated to reverse the effects of the muscle relaxants given during surgery in the United States.

The company has launched Sugammadex injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the US, Dr Reddy's Laboratories Ltd said in a statement.

Bridion is a registered trademark of Merck Sharp & Dohme BV, it added.

Advertisement

The launch expands the company's hospital portfolio and reinforces its commitment to improving patient access to affordable, high-quality medicines.

Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global supply network. The company has launched the product on the first day of generic availability in the US, it added.

Sugammadex Injection (100mg/ml) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.

The Bridion brand (100mg/ml) had US sales of approximately USD 1.6 billion for the latest 12-month period ended May 2026, according to IQVIA National Sales Perspectives, the statement said.

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News